{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:11:21Z","timestamp":1761487881237},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,6,29]],"date-time":"2007-06-29T00:00:00Z","timestamp":1183075200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s10620-007-9885-2","type":"journal-article","created":{"date-parts":[[2007,6,28]],"date-time":"2007-06-28T05:41:19Z","timestamp":1183009279000},"page":"564-570","source":"Crossref","is-referenced-by-count":43,"title":["Phase-II Study of Gemcitabine and Cisplatin in Patients with Metastatic Biliary and Gallbladder Cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Jeffrey A.","family":"Meyerhardt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew X.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Blaszkowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig C.","family":"Earle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew H.","family":"Kulke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles S.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,6,29]]},"reference":[{"key":"9885_CR1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","volume":"56","author":"A Jemal","year":"2006","unstructured":"Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106\u2013130","journal-title":"CA Cancer J Clin"},{"key":"9885_CR2","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"9885_CR3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/01.coc.0000135924.94955.16","volume":"27","author":"C Eng","year":"2004","unstructured":"Eng C, Ramanathan RK, Wong MK et al (2004) A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 27:565\u2013569","journal-title":"Am J Clin Oncol"},{"key":"9885_CR4","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","volume":"19","author":"V Gebbia","year":"2001","unstructured":"Gebbia V, Giuliani F, Maiello E et al (2001) Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19:4089\u20134091","journal-title":"J Clin Oncol"},{"key":"9885_CR5","first-page":"783","volume":"48","author":"S Kubicka","year":"2001","unstructured":"Kubicka S, Rudolph KL, Tietze MK et al (2001) Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48:783\u2013789","journal-title":"Hepatogastroenterology"},{"key":"9885_CR6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000070622","volume":"49","author":"MH Lin","year":"2003","unstructured":"Lin MH, Chen JS, Chen HH et al (2003) A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 49:154\u2013158","journal-title":"Chemotherapy"},{"key":"9885_CR7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-005-0095-3","volume":"57","author":"T Okusaka","year":"2006","unstructured":"Okusaka T, Ishii H, Funakoshi A et al (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57:647\u2013653","journal-title":"Cancer Chemother Pharmacol"},{"key":"9885_CR8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jjco\/hyi021","volume":"35","author":"JS Park","year":"2005","unstructured":"Park JS, Oh SY, Kim SH et al (2005) Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 35:68\u201373","journal-title":"Jpn J Clin Oncol"},{"key":"9885_CR9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1008352123009","volume":"12","author":"M Penz","year":"2001","unstructured":"Penz M, Kornek GV, Raderer M et al (2001) Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 12:183\u2013186","journal-title":"Ann Oncol"},{"key":"9885_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","volume":"22","author":"N Tsavaris","year":"2004","unstructured":"Tsavaris N, Kosmas C, Gouveris P et al (2004) Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 22:193\u2013198","journal-title":"Invest New Drugs"},{"key":"9885_CR11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2407-5-61","volume":"5","author":"S Delius von","year":"2005","unstructured":"von Delius S, Lersch C, Schulte-Frohlinde E et al (2005) Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. BMC Cancer 5:61","journal-title":"BMC Cancer"},{"key":"9885_CR12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cncr.20753","volume":"103","author":"SR Alberts","year":"2005","unstructured":"Alberts SR, Al-Khatib H, Mahoney MR et al (2005) Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 103:111\u2013118","journal-title":"Cancer"},{"key":"9885_CR13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andre","year":"2004","unstructured":"Andre T, Tournigand C, Rosmorduc O et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15:1339\u20131343","journal-title":"Ann Oncol"},{"key":"9885_CR14","first-page":"23","volume":"17","author":"P Bhargava","year":"2003","unstructured":"Bhargava P, Jani CR, Savarese DM et al (2003) Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Williston Park) 17:23\u201326","journal-title":"Oncology (Williston Park)"},{"key":"9885_CR15","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/cncr.21591","volume":"104","author":"JY Cho","year":"2005","unstructured":"Cho JY, Paik YH, Chang YS et al (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced\/metastatic biliary tract carcinoma. Cancer 104:2753\u20132758","journal-title":"Cancer"},{"key":"9885_CR16","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/sj.bjc.6601736","volume":"90","author":"DC Doval","year":"2004","unstructured":"Doval DC, Sekhon JS, Gupta SK et al (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90:1516\u20131520","journal-title":"Br J Cancer"},{"key":"9885_CR17","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.bjc.6601796","volume":"90","author":"C Hsu","year":"2004","unstructured":"Hsu C, Shen YC, Yang CH et al (2004) Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil\/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Br J Cancer 90:1715\u20131719","journal-title":"Br J Cancer"},{"key":"9885_CR18","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cncr.21741","volume":"106","author":"ST Kim","year":"2006","unstructured":"Kim ST, Park JO, Lee J et al (2006) A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339\u20131346","journal-title":"Cancer"},{"key":"9885_CR19","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","volume":"23","author":"JJ Knox","year":"2005","unstructured":"Knox JJ, Hedley D, Oza A et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23:2332\u20132338","journal-title":"J Clin Oncol"},{"key":"9885_CR20","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/annonc\/mdh172","volume":"15","author":"JJ Knox","year":"2004","unstructured":"Knox JJ, Hedley D, Oza A et al (2004) Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol 15:770\u2013774","journal-title":"Ann Oncol"},{"key":"9885_CR21","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/annonc\/mdh096","volume":"15","author":"GV Kornek","year":"2004","unstructured":"Kornek GV, Schuell B, Laengle F et al (2004) Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol 15:478\u2013483","journal-title":"Ann Oncol"},{"key":"9885_CR22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1023\/A:1016209901417","volume":"20","author":"R Kuhn","year":"2002","unstructured":"Kuhn R, Hribaschek A, Eichelmann K et al (2002) Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 20:351\u2013356","journal-title":"Invest New Drugs"},{"key":"9885_CR23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/annonc\/mdi046","volume":"16","author":"S Thongprasert","year":"2005","unstructured":"Thongprasert S, Napapan S, Charoentum C et al (2005) Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16:279\u2013281","journal-title":"Ann Oncol"},{"key":"9885_CR24","unstructured":"Valle W, Wasan H, Johnson P et al (2006) Gemcitabine, alone or in combination with cisplatin, in patients with advanced or metastatic cholangiocarcinoma (CC) and other biliary tract tumors: a multicenter, randomized, phase II (the UK ABC-01) study, Gastrointestinal Cancer Symposium, pp Abstr 98"},{"key":"9885_CR25","first-page":"521","volume":"2","author":"AM Bergman","year":"1996","unstructured":"Bergman AM, Ruiz van Haperen VW, Veerman G et al (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521\u2013530","journal-title":"Clin Cancer Res"},{"key":"9885_CR26","first-page":"72","volume":"22","author":"GJ Peters","year":"1995","unstructured":"Peters GJ, Bergman AM, Ruiz van Haperen VW et al (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72\u201379","journal-title":"Semin Oncol"},{"key":"9885_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9885_CR28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.2005.03.8315","volume":"24","author":"CM Rocha Lima","year":"2006","unstructured":"Rocha Lima CM, Flores AM (2006) Gemcitabine doublets in advanced pancreatic cancer: should we move on? J Clin Oncol 24:327\u2013329","journal-title":"J Clin Oncol"},{"key":"9885_CR29","doi-asserted-by":"crossref","unstructured":"Heinemann V, Labianca R, Hinke A et al (2006) Superiority of gemcitabine plus platinum analog compared to gemcitabine alone in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR\/GISCAD Intergroup Study and a German Multicenter Study, Gastrointestinal Cancer Symposium, pp Abstr 96","DOI":"10.1093\/annonc\/mdm283"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-007-9885-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-007-9885-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-007-9885-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:43:45Z","timestamp":1559245425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-007-9885-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,29]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["9885"],"URL":"https:\/\/doi.org\/10.1007\/s10620-007-9885-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,29]]}}}